JOIN THE FRONTIER OF PRECISION ONCOLOGY
Frontier Diagnostics is developing blood-based diagnostic tools that help clinicians monitor cancer activity in real time. Our work focuses on improving how cancer is tracked and treated, using non-invasive methods to deliver earlier, more personalised insights. We are currently raising investment through the Enterprise Investment Scheme (EIS) and invite interest from individuals familiar with early-stage opportunities.
INVESTMENT HIGHLIGHTS
Diagnostics platform built on ISO-accredited laboratory infrastructure
Leadership team with backgrounds in oncology, diagnostics, clinical research, and regulated healthcare delivery
Proprietary liquid biopsy methods designed to detect and analyse circulating tumour cells (CTCs)
Operational presence in the UK and Europe, with near-term global expansion
Plans to incorporate AI and digital monitoring to support clinicians and patients across the full treatment cycle
WHY WE’RE RAISING CAPITAL
Investment proceeds will be used to:
- Extend our diagnostic testing range
- Develop AI tools and reporting software
- Build out our UK laboratory capacity
- Support international partnerships and commercial rollout
- Launch a digital monitoring platform for patients and clinicians
UNDERSTANDING THE ENTERPRISE INVESTMENT SCHEME (EIS)
The Enterprise Investment Scheme (EIS) is a UK government initiative that encourages investment in early-stage companies by offering a range of tax reliefs to investors.
Key EIS tax benefits include:
- 30% Income Tax Relief: Available on investments up to £1 million per tax year
- Capital Gains Tax Deferral: Defer tax on gains reinvested into an EIS-qualifying company
- Tax-Free Growth: No Capital Gains Tax payable on profits if shares are held for at least three years
- Loss Relief: If the investment is realised at a loss, it may be offset against income or capital gains tax
- Inheritance Tax Relief: After two years, EIS shares are exempt from IHT
You can explore your potential tax benefits using our EIS Calculator.
NEXT STEPS
To access our full investor documentation and executive summary, please complete the form.
Once submitted, a member of our team will be in touch to provide access and answer any questions.